SUBJECT ELIGIBILITY

        Note: During the period of cell procurement and CAR.κ.28 T cell production, subjects are
        allowed to receive additional standard of care chemotherapy to stabilize their disease if
        the treating physician feels it is in the subject's best interest. For subjects requiring
        bridging chemotherapy while awaiting manufacture of their CAR.κ.28 T-cells, details
        regarding treatment(s) administered including dose, frequency, number of cycles, etc. will
        be collected.

        Inclusion Criteria for the Study

        Unless otherwise noted, subjects must meet all of the following criteria to participate in
        this study:

          1. Written informed consent and HIPAA authorization for release of personal health
             information.

          2. Adults ≥18 years of age.

          3. Diagnosis of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic
             lymphoma OR histologically confirmed B-cell NHL, including the following types defined
             by WHO 2016:

             Aggressive Lymphomas:

               -  DLBCL not otherwise specified (NOS)

               -  T cell/histiocyte rich large B cell lymphoma; primary cutaneous DLBCL, leg type;
                  EBV-positive DLBCL NOS; DLBCL associated with chronic inflammation; Lymphomatoid
                  granulomatosis; Large B-cell lymphoma with IRF4 rearrangement; Intravascular
                  large B-cell lymphoma; ALK-positive large B-cell lymphoma

               -  Primary mediastinal (thymic) large B-cell lymphoma

               -  High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement; high
                  grade B-cell lymphoma, NOS

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and
                  classical Hodgkin lymphoma

               -  Transformation of indolent lymphoma or CLL to DLBCL will also be included

               -  Burkitt lymphoma

             Indolent Lymphomas:

               -  Follicular lymphoma grade 1-3b

               -  Splenic marginal zone lymphoma

               -  Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

               -  Nodal marginal zone lymphoma

               -  Mantle cell lymphoma

               -  Subjects with CNS disease will not be excluded as long it has been stable for 3
                  months

             Subjects with bone marrow only involvement are eligible

          4. Subjects relapsed after autologous or allogeneic stem cell transplant are eligible for
             this study.

          5. Subjects who have received prior CD19-directed CAR therapies for relapsed/refractory
             disease are eligible for this study. However, at least 3 months must have passed since
             the subject received CD19 CAR-T cells.

          6. Patients with aggressive lymphomas must have relapsed or refractory disease after
             having received at least 2 prior lines of systemic therapy, including, at a minimum:

               -  An anti-CD20 monoclonal antibody

               -  An anthracycline containing chemotherapy regimen (if eligible)

               -  An autologous stem cell transplant (if eligible)

          7. For indolent lymphomas, subjects must have received at least 2 prior lines of therapy
             for their lymphoma

          8. Subjects with specifically relapsed/refractory chronic lymphocytic leukemia/small
             lymphocytic lymphoma must have received at least 2 prior therapy regimens which can
             include, but not limited to:

               -  A combination of an anti-CD20 monoclonal antibody and an alkylating agent, OR

               -  A Bruton's Tyrosine Kinase Inhibitor, OR

               -  A BCL-2 inhibitor in combination with an anti-CD20 monoclonal antibody

          9. Subjects with a prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial.

         10. Kappa-positive expression on lymphoma or CLL/SLL tissue sample, or kappa restriction
             on flow cytometry (archival or fresh) as confirmed by institutional hematopathology
             standard (result must be confirmed at the time of cell procurement).

         11. Karnofsky score of > 60% (see Appendix C).

         12. Female subjects of childbearing potential must be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study, and for 6 months after the study is concluded. Female subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year. The two birth control methods can be composed of:
             two barrier methods or a barrier method plus a hormonal method to prevent pregnancy.
             Female subjects of childbearing potential will also be instructed to tell their male
             partners to use a condom.

        Exclusion Criteria for the Study

        Subjects meeting any of the following exclusion criteria will not be able to participate in
        this study (procurement, lymphodepletion and cell infusion):

          1. A diagnosis of lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia or multiple
             myeloma.

          2. A history of intolerance to bendamustine or fludarabine. Note: subjects with known
             history of intolerance to bendamustine may be considered for lymphodepletion with
             cyclophosphamide and fludarabine at the discretion of the clinical investigator.

          3. Subject is pregnant or lactating.

          4. Tumor in a location where enlargement could cause airway obstruction.

          5. Current use of systemic corticosteroids at doses ≥10 mg prednisone daily or its
             equivalent; those receiving <10 mg daily may be enrolled at discretion of
             investigator.

          6. Active infection with HTLV, HCV (can be pending at the time of cell procurement; only
             those samples confirming lack of active infection will be used to generate transduced
             cells) defined as not being well controlled on therapy as well as no history of HIV.
             Subjects are required to have negative HIV antibody, negative HTLV1 and HTLV2
             antibodies, negative hepatitis B surface antigen, and negative HCV antibody or viral
             load.

          7. Subjects who are positive for hepatitis B surface antigen (can be pending at the time
             of cell procurement; only those samples confirming lack of active infection will be
             used to generate transduced cells) are excluded. Subjects who are hepatitis B surface
             antigen negative but hepatitis B core antibody positive must have their hepatitis B
             viral load checked. These subjects will be excluded if their viral load is positive at
             baseline (when tested during screening for procurement). Subjects who are core
             antibody positive and viral load negative at baseline will be considered eligible.

        Eligibility Criteria to be Met Prior to Procurement

          1. Subject has signed a consent to undergo cell procurement.

          2. Evidence of adequate organ function as defined by:

               -  Hemoglobin ≥ 8.0 g/dL (transfusion independent for 2 weeks prior to enrollment)

               -  Total bilirubin <1.5 × ULN (subjects with Gilbert's syndrome may be enrolled
                  despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5
                  × ULN)

               -  AST and ALT < 5x ULN

               -  Pulse oximetry of >90% on room air

               -  Creatinine ≤1.5x ULN or Creatinine Clearance (CrCl) >60 mL/min per Cockcroft and
                  Gault (see Appendix F).

          3. Imaging results from within 120 days prior to procurement to assess presence of active
             disease.

          4. Confirmed kappa-positive expression on lymphoma or CLL/SLL tissue or bone marrow
             sample (archival or fresh) as confirmed by pathology.

          5. Subject has adequate cardiac function, defined as:

               -  No ECG evidence of acute ischemia

               -  No ECG evidence of active, clinically significant conduction system abnormalities

               -  Prior to study entry, any ECG abnormality at screening not felt to put the
                  subject at risk has to be documented by the investigator as not medically
                  significant

               -  No uncontrolled angina or severe ventricular arrhythmia

               -  Left ventricular ejection fraction (LVEF) >40% as measured by ECHO, with no
                  additional evidence of decompensated heart failure, performed within 30 days
                  prior to procurement

          6. In women of child-bearing potential, negative serum pregnancy test within 72 hours
             prior to procurement or documentation that the subject is post-menopausal.
             Post-menopausal status must be confirmed with documentation of absence of menses for >
             1 year.

        Eligibility Criteria to be Met Prior to Lymphodepletion

          1. Written informed consent to enroll in the CAR-T cell therapy trial must be obtained
             prior to lymphodepletion.

          2. The last bridging therapy should be completed at least 3 weeks prior to
             lymphodepletion. Subjects who have received bridging therapy will be reassessed with
             imaging within 5 days prior to lymphodepletion and at least 3 weeks after bridging
             therapy. If a patient did not receive bridging chemotherapy, they will e imaged within
             10 days prior to lymphodepletion.

          3. Adequate organ function per the following criteria are required prior to
             lymphodepletion:

               -  Adequate bone marrow function, as defined by:

                    -  ANC >1.0 × 109/L

                    -  Platelets >50 × 109/L unless related to lymphoma involvement (independent of
                       transfusion within 7 days of lymphodepletion)

               -  Total bilirubin ≤1.5× ULN (subjects with Gilbert's syndrome may be enrolled
                  despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5×
                  ULN)

               -  AST and ALT ≤ 5× ULN

               -  Pulse oximetry of > 90% on room air

               -  Creatinine <1.5x ULN or Creatinine clearance (CrCl) >60 mL/min per Cockcroft and
                  Gault (see Appendix F),

          4. If subjects display any clinical signs or symptoms of cardiac dysfunction after
             receiving bridging chemotherapy, they will undergo repeat ECG and ECHO to reassess
             their cardiac function and status

          5. In female subjects of childbearing potential, a negative serum pregnancy test within
             72 hours prior to l ymphodepletion or documentation that the subject is
             post-menopausal or has been surgically sterilized.

             Post-menopausal status must be confirmed with documentation of absence of menses for >
             1 year.

          6. In subjects with CLL/SLL, a bone marrow biopsy within 28 days prior to
             lymphodepletion.

          7. Subjects must have autologous transduced activated T-cells that meet the Certificate
             of Analysis (CofA) acceptance criteria.

          8. Has not received any investigational agents or received any tumor vaccines within the
             previous six weeks prior to lymphodepletion.

          9. Has not received chemotherapy or immunotherapy within the previous 3 weeks prior to
             lymphodepletion.

         10. Subjects may not be receiving strong inhibitors of CYP1A2 (e.g., fluvoxamine,
             ciprofloxacin) up through

        72 hours after the last dose of bendamustine, as these may increase plasma concentrations
        of bendamustine, and decrease plasma concentrations of its metabolites. See
        http://medicine.iupui.edu/clinpharm/ddis/ for an updated list of strong inhibitors of
        CYP1A2 (additionally, see Appendix I: Prohibited Medications or Those to Use with Caution)
        11 Subject is not taking a prohibited or contraindicated medication listed in Section 5.12
        and Appendix I: Prohibited Medications or Those to Use with Caution prior to
        lymphodepletion. Contraindicated medications should be discontinued at least two weeks
        prior to the scheduled lymphodepletion or by at least 5 half-lives of the contraindicated
        medication, whichever is shorter. 12 No evidence of uncontrolled infection or sepsis.

        Eligibility Criteria to be Met Prior to Cell Infusion After Lymphodepletion

          1. No evidence of uncontrolled infection or sepsis.

          2. Evidence of adequate organ function as defined by:

               1. Total bilirubin ≤2 × ULN, unless attributed to Gilbert's syndrome

               2. AST < 5 × ULN

               3. ALT < 5 × ULN

               4. Creatinine ≤ 1.5 × ULN or Creatinine clearance (CrCl) >60 mL/min per Cockcroft
                  and Gault (see Appendix F)

          3. Subject has no clinical indication of rapidly progressing disease in the opinion of
             the clinical investigator.

          4. Subject is a good candidate for treatment with CAR.κ.28 cell product per the clinical
             investigator's discretion.